- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00120939
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
April 2, 2009 updated by: Pharmacyclics LLC.
Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Chemotherapy in the Treatment of Advanced Solid Tumors
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers.
Secondly, tumor response to the combined treatment, drug levels in the body, and drug interactions will be evaluated.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
25
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- At least 18 years old
- Metastatic, or unresectable solid tumors from breast, head, and neck, gastrointestinal, genitourinary, lung, or ovarian cancer or recurrent glioblastoma multiforme
- ECOG performance status score either 0, 1, or 2
- Willing and able to provide written informed consent
Exclusion Criteria:
- Greater than two prior cytotoxic regimens
- Laboratory values showing adequate function of bone marrow, liver, and kidneys
- Uncontrolled hypertension
- Known sensitivity to or intolerable adverse effects from taxanes (eg. paclitaxel, docetaxel) or polysorbate 80
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Determine the Dose Limiting Toxicity at 8 weeks (2 cycles), and the Maximum Tolerated Dose at 24 weeks.
|
Secondary Outcome Measures
Outcome Measure |
---|
Tumor response rate 8, 16 and 24 weeks, and common PK parameters at 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gurkamal Chatta, MD, University of Pittsburgh Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 7, 2022
Primary Completion
December 7, 2022
Study Completion
December 7, 2022
Study Registration Dates
First Submitted
July 12, 2005
First Submitted That Met QC Criteria
July 12, 2005
First Posted (Estimate)
July 19, 2005
Study Record Updates
Last Update Posted (Estimate)
April 3, 2009
Last Update Submitted That Met QC Criteria
April 2, 2009
Last Verified
May 1, 2007
More Information
Terms related to this study
Keywords
- Breast Cancer
- Head and Neck Cancer
- Lung Cancer
- Glioblastoma Multiforme
- Gastric Cancer
- Prostate Cancer
- Pancreatic Cancer
- Cervical Cancer
- Colorectal Cancer
- Ovarian Cancer
- Endometrial Cancer
- Advanced Cancer
- Metastatic Cancer
- Esophageal Cancer
- Bladder Cancer
- Colon Cancer
- Kidney Cancer
- Gastrointestinal Cancer
- Genitourinary Cancer
- Recurrent Cancer
- Stomach Cancer
- Throat Cancer
- Renal Cancer
Additional Relevant MeSH Terms
- Digestive System Diseases
- Skin Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Gastrointestinal Diseases
- Endocrine Gland Neoplasms
- Genital Neoplasms, Male
- Breast Diseases
- Prostatic Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplasms
- Breast Neoplasms
- Prostatic Neoplasms
- Lung Neoplasms
- Ovarian Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Antineoplastic Agents
- Photosensitizing Agents
- Dermatologic Agents
- Motexafin gadolinium
Other Study ID Numbers
- PCYC-0212
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Neoplasms
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruiting
-
Sun Yat-sen UniversityUnknownGastrointestinal CancersChina
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompleted
-
Novartis PharmaceuticalsActive, not recruitingNeoplasms, Gastrointestinal TractChina, Canada, Estonia, Italy, Turkey, Argentina, Israel, Netherlands, Poland, Russian Federation, Thailand, Brazil, Chile, Hong Kong, Hungary, India, Mexico, Peru, Taiwan, Ukraine, United States, Korea, Republic of, Puerto Rico
-
Peking University Cancer Hospital & InstituteActive, not recruitingGastrointestinal CancerChina
-
Brigette MaRecruiting
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdJiangsu Alphamab Biopharmaceuticals Co., LtdRecruitingAdvanced Gastrointestinal TumorsChina
-
Boehringer IngelheimCompletedGastrointestinal Cancer, MetastaticBelgium, United States, France, Japan, China
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Henan Cancer HospitalUnknownAdvanced Gastrointestinal TumorsChina
Clinical Trials on Motexafin Gadolinium
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI)Active, not recruitingProstate CancerUnited States
-
Pharmacyclics LLC.CompletedLymphoma | Leukemia | Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Pharmacyclics LLC.CompletedKidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital NeoplasmsUnited States
-
Pharmacyclics LLC.TerminatedHead and Neck Cancer | Oropharynx Cancer | Larynx Cancer | Hypopharynx CancerUnited States
-
Pharmacyclics LLC.CompletedCarcinoma, Bronchogenic | Non-Small-Cell Lung CarcinomaUnited States
-
Pharmacyclics LLC.CompletedAdenocarcinoma | Lung Neoplasms | Non-Small-Cell Lung CarcinomaUnited States, Canada
-
Pharmacyclics LLC.CompletedMultiple MyelomaUnited States
-
Pharmacyclics LLC.TerminatedChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Pharmacyclics LLC.CompletedCarcinoma, Non-Small-Cell Lung | Brain Neoplasms | Metastases, NeoplasmUnited States, France, Belgium, Germany, Canada, Netherlands, Austria, Australia
-
University of PittsburghNational Cancer Institute (NCI)CompletedPancreatic Cancer | Gallbladder Cancer | Extrahepatic Bile Duct CancerUnited States